Fig. 4

Effect of Sora-MNC on FLT3 signaling and gene expression profile. A Scheme of three major downstream signaling pathways of FLT3. B Western blot of MOLM-14 and MV-4-11 cells subjected to different treatments (Sora: free sorafenib, MNC: Sora-MNC, HAE: HA-EGCG, E: EGCG, Ctrl: untreated control). The numbers represent p-S6/S6 ratios. C Hierarchical clustering heatmap of differentially expressed genes (DEGs). Gradient scale represents upregulation (red) and downregulation (blue). D Venn diagram showing the number of DEGs in each experimental group and the overlaps between groups. E The top seven pathways identified by KEGG enrichment analysis. Asterisks indicate significantly enriched pathways with an adjusted P value (padj) < 0.05. F Heatmap of representative DEGs involved in the TCA cycle, aminoacyl-tRNA synthetase (ARS) and mTOR signaling. G qPCR validation of RNA-seq data. Mean ± SD (n = 3). H Scheme of the mechanism of anti-leukemic action of Sora-MNC. Red arrows highlight downregulation of gene expression in response to Sora-MNC treatment